SAVA - Cassava Sciences warns of potential clinical hold on simufilam in recent 10-K filing

Cassava Sciences (SAVA +2.4%) has warned that it may face a clinical hold on its trials for simufilam after the U.S. FDA imposed them this year on two competitors that are also working on Alzheimer's candidates. The notification was tucked away in Cassava's (SAVA +2.7%) 10-K annual report filing on Feb. 28.  The company noted the holds on Cortexyme (CRTX +5.4%) and Denali Therapeutics (DNLI +0.4%) in regards to their Alzheimer's candidates, both done in January. Cortexyme (CRTX +5.4%) said it would provide updates after further engagement with the agency and Denali (DNLI +0.4%) did not provide details behind its hold.  "A clinical hold may require us to spend significant resources over many months to address the root causes of FDA's concerns," Cassava (SAVA +2.7%) said in the filing. "We may not find and successfully address such root causes, which could adversely affect our business. "  "If we are on

For further details see:

Cassava Sciences warns of potential clinical hold on simufilam in recent 10-K filing